10-K annual report · filed Nov 16, 2026

Twist Bioscience Corp (TWST) FY2026 10-K Annual Report

Short answer

Twist Bioscience Corp (TWST) filed its fiscal 2026 10-K annual report with the SEC on Nov 16, 2026. It reported revenue of $459M (+22.0% year over year) and net income of −$130M.

  • Top risk flagged: Biosecurity regulation: Executive Order 14292 and proposed H.R. 3029 could increase nucleic-acid screening costs, turnaround times, and fulfillment constraints

FY2026 key financial metrics · XBRL

Revenue
$459M
+22.0% YoY
Net income
−$130M
−67.6% YoY
Operating margin
-30.4%
+5.8 pp YoY
EPS (diluted)
−$2.08
−60.0% YoY
ROE
-14.7%
+1.8 pp YoY
Operating cash flow
−$41M
+13.0% YoY

Source: XBRL data from the Twist Bioscience Corp (TWST) FY2026 10-K on SEC EDGAR. USD.

Twist Bioscience Corp FY2026 10-K analysis

AI summary of each section, grounded in the filing text

Business Overview

  • Silicon-based DNA synthesis platform: customizable DNA, proteins and sequencing workflow solutions across life sciences markets
  • Fiscal 2026 segment reorganization: combined synthetic biology and antibody discovery into DNA Synthesis and Protein Solutions
  • AI drug discovery emphasis: Twist became a protein and data partner, with substantially increased customer demand
  • February 2026 bispecific expansion: co-exclusive Invenra B-Body license and minority equity investment
  • Revenue $459.4 million from approximately 4,100 customers, with 1,080 employees as of September 30, 2026

Management Discussion & Analysis

  • Revenue $459.4M, up 22% YoY from $376.6M, driven by DNA Synthesis and Protein Solutions and NGS Applications
  • Gross margin 52.4% vs 50.7%; operating loss $139.5M vs $136.3M
  • Best segment DNA Synthesis and Protein Solutions, revenue $221.9M, up $53.4M; weakest growth NGS Applications, revenue $237.5M, up $29.4M
  • Operating cash use $41.4M; capex $47.6M; financing cash $446.7M, including $327.7M offering proceeds and $97.1M ATM proceeds
  • Outlook: AI-enabled drug discovery demand expected to grow in fiscal 2027; approximately $150M capex planned over two years, with reimbursement and regulatory risks

Risk Factors

  • Biosecurity regulation: Executive Order 14292 and proposed H.R. 3029 could increase nucleic-acid screening costs, turnaround times, and fulfillment constraints
  • Geopolitical exposure: International customers generated 41% of fiscal 2026 revenue amid tariffs, Russia-China tensions, and Israel-Hamas conflict
  • Supply-chain vulnerability: One single-source supplier provides a critical DNA-synthesis component Twist cannot manufacture internally
  • Competitive disruption: Integrated DNA Technologies, GenScript, and emerging silicon-chip technologies threaten Twist’s platform advantage
  • Financial risk: Net loss $130.2 million and accumulated deficit $1,449.8 million as of September 30, 2026, with potential further equity dilution

Generated from the filing text; verify against the original. How to read a 10-K

Other Twist Bioscience Corp annual reports

Ask about this 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.